3179.T Syuppin Co., Ltd.

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

RIZIN Decade wrapped up 2024 for the mixed martial arts world, and debuting MMA fighter Daichi Tomizawa took full advantage of appearing on the Japanese promotion’s annual New Year’s Eve extravaganza.

Adults aged ≥20 years without a diagnosis of hypertension or antihypertensive medication use and a high office BP (≥130/80 mm Hg) who participated in the National Health and Nutrition Examination ...

Daiichi Sankyo has made a little bit of pharma industry history, becoming the first drugmaker to win approval in Japan for a therapy for cancer based on a virus that selectively kills malignant cells.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

8316.T Sumitomo Mitsui Financial Group, Inc.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Dai Ichi Karkaria Ltd., incorporated in the year 1960, is a Small Cap company (having a market cap of Rs 293.28 Crore) operating in Chemicals sector. Dai Ichi Karkaria Ltd. key Products/Revenue ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...